The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback